New FDA Approvals: FDA Approves First Abraxane Generic

  • Nov 14, 2024

    Oct. 8: The FDA approved Sandoz Inc.’s paclitaxel for the treatment of metastatic breast cancer, after failure of combination chemotherapy for metastatic disease or relapse within six months of adjuvant chemotherapy. It is the first FDA-approved generic of Abraxane from Abraxis BioScience LLC, a division of Bristol Myers Squibb. The agent is available as a 100 mg single-dose vial of lyophilized powder. Recommended dosing is 260 mg/m2 via a 30-minute intravenous infusion every three weeks. Drugs.com lists the price of one 100 mg vial of Abraxane as more than $1,673. Read more
    © 2024 MMIT
  • Angela Maas

    Angela has an extensive background of editing, reporting and writing for trade and consumer publications. She has written Radar on Specialty Pharmacy since she joined AIS Health in 2005 and has broad knowledge of the various issues at play within the space. She also has written for Spotlight on Market Access since its 2017 launch. Before joining AIS Health, she was managing editor at Employee Benefit News and Employee Benefit News Canada and managing editor at Hem Aware (a hemophilia publication), Lupus Living and Momentum (a multiple sclerosis publication). She has a B.A. in English and an M.A. in British literature from Arizona State University.

The Latest
Meet Our Reporters

Meet Our Reporters

×